Analysis of the functions, efficacy and scope of application of Asnib/Asiminib

Asciminib (Asciminib) is a new type of tyrosine kinase inhibitor, belonging to the STI-571 classBCR-ABL inhibitor is a new mechanism drug. Its unique feature is that it binds to the ABL receptor through the "myristoyl pocket” site to achieve specific inhibition of BCR-ABL fusion protein. This mechanism of action is different from traditional first- or second-generation BCR-ABL inhibitors, allowing Asciminib to show unique clinical advantages in patients with drug-resistant or relapsed chronic myelogenous leukemia (CML). Its main function is to inhibit the abnormal signaling pathway mediated by BCR-ABL, thereby preventing leukemia cell proliferation and promoting apoptosis.

In terms of clinical indications, Asciminib is mainly used for patients with chronic myelogenous leukemia (CML-CP) in the chronic phase, especially for imatinib (Imatinib), dasatinib (Dasatinib) or nilotinib (Nilotinib) treatment. In addition, Asciminib provides a new treatment option for CML patients carrying the T315I mutation, as this mutation often results in the loss of efficacy of various other BCR-ABL inhibitors. AsciminibBy selectively binding to the myristoyl site, it is not only effective against wild-type BCR-ABL but also shows inhibitory effects on some drug-resistant mutations, broadening the scope of targeted therapy.

In terms of efficacy, clinical studies have shown that Asciminib can significantly improve the complete cytological response rate (CCyR) and molecular response rate (MMR). For patients with previous multi-line drug resistance, the overall response rate of Asciminibtreatment for 12 months is significantly higher than that of the control group. At the same time, the safety is relatively good, and the adverse reactions are mostly mild to moderate, such as mild thrombocytopenia, leukopenia, musculoskeletal pain or mild gastrointestinal reactions. Compared with traditional TKIs, Asciminib can be used as a monotherapy or in combination with other BCR-ABL inhibitors to improve efficacy or address resistance to specific mutations.

In general, Asciminib (Asciminib) achieves precise targeted inhibition of leukemia cells through an innovative mechanism, providing a new treatment option for patients with chronic phase CML drug resistance or relapse. It has stable efficacy and good tolerability, and is especially suitable for patients with T315I mutation or those who have failed multiple lines of treatment. In the future, with the accumulation of more clinical data, Asciminib is expected to expand the scope of indications and play a greater role in personalized treatment and combination drug strategies, providing patients with chronic myelogenous leukemia with hope for long-term disease control.

Reference materials:https://www.drugs.com/